Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial
Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial
Aims: Fractional flow reserve (FFRCT) using computed tomography coronary angiography (CTCA) determines both the presence of coronary artery disease and vessel-specific ischaemia. We tested whether an evaluation strategy based on FFRCT would improve economic and clinical outcomes compared with standard care. Methods and results: Overall, 1400 patients with stable chest pain in 11 centres were randomized to initial testing with CTCA with selective FFRCT (experimental group) or standard clinical care pathways (standard group). The primary endpoint was total cardiac costs at 9 months. Secondary endpoints were angina status, quality of life, major adverse cardiac and cerebrovascular events, and use of invasive coronary angiography. Randomized groups were similar at baseline. Most patients had an initial CTCA: 439 (63%) in the standard group vs. 674 (96%) in the experimental group, 254 of whom (38%) underwent FFRCT. Mean total cardiac costs were higher by £114 (+8%) in the experimental group, with a 95% confidence interval from -£112 (-8%) to +£337 (+23%), though the difference was not significant (P = 0.10). Major adverse cardiac and cerebrovascular events did not differ significantly (10.2% in the experimental group vs. 10.6% in the standard group) and angina and quality of life improved to a similar degree over follow-up in both randomized groups. Invasive angiography was reduced significantly in the experimental group (19% vs. 25%, P = 0.01). Conclusion: A strategy of CTCA with selective FFRCT in patients with stable angina did not differ significantly from standard clinical care pathways in cost or clinical outcomes, but did reduce the use of invasive coronary angiography.
Computed tomography coronary angiography, Cost analysis, Fractional flow reserve (FFR ), Myocardial, Quality of life, Randomized controlled trial, Stable angina
3844-3852
Curzen, N
70f3ea49-51b1-418f-8e56-8210aef1abf4
Nicholas, Z
266e88f3-01a5-4251-8353-29d7aee0ab84
Stuart, B
626862fc-892b-4f6d-9cbb-7a8d7172b209
Wilding, S
1f316b8b-db59-4289-b6aa-183f957f3470
Hill, K
ac2c30a1-e493-4dc0-aa8e-b7d1d644f7c2
Shambrook, J
4ac185d1-8863-4ec7-b338-950236e86e36
Eminton, Z
44904d98-97be-4080-9a84-bf5742525f8e
Ball, D
130db4c5-0721-4d6d-88d3-e502f5610b55
Barrett, C
22ed24c2-7305-4293-97df-4a27d9dd4e0a
Johnson, L
9f854b21-5ab6-42b1-a11e-f9871128f8fa
Nuttall, J
154aec0a-05f2-4379-918e-9c36767fdc4c
Fox, K.
cb14d631-49e0-4eaa-9c31-bc8fa56bcf62
Connolly, D
6067c40f-49e1-4d57-be94-b8753eee8230
O'Kane, P
2b488230-e0b8-4bec-9eb6-b6e071d25cd8
Hobson, A
7d245a8e-2a69-417c-81ae-5d8c6b775897
Chauhan, A
8e0ac32a-b41d-44cf-9e17-2395913dfee5
Uren, N
d13a24cc-01a4-4a8c-a522-b1b5fd872e4a
Mccann, G P
8e61a5f4-0764-4adf-bc9c-5abba82425fc
Berry, C
9d729b5b-d244-42bc-a44e-ad74874d9d2d
Carter, J
e05be2f9-991d-4476-bb50-ae91606389da
Roobottom, C
990efe11-c995-4beb-b262-59ae97269bad
Mamas, M
41515b72-75ff-4922-bb9f-8f9c63f9f5af
Rajani, R
f2c3a772-ab0a-459e-b820-e4dcc0339d41
Ford, I
02bcd593-64e4-4cb9-87e3-9a6efe4d155c
Douglas, P
003c913d-4d22-44e3-a74c-83ee06241947
Hlatky, M.A.
43f00437-a3e4-4f81-aed9-5b0ca52cd86e
1 October 2021
Curzen, N
70f3ea49-51b1-418f-8e56-8210aef1abf4
Nicholas, Z
266e88f3-01a5-4251-8353-29d7aee0ab84
Stuart, B
626862fc-892b-4f6d-9cbb-7a8d7172b209
Wilding, S
1f316b8b-db59-4289-b6aa-183f957f3470
Hill, K
ac2c30a1-e493-4dc0-aa8e-b7d1d644f7c2
Shambrook, J
4ac185d1-8863-4ec7-b338-950236e86e36
Eminton, Z
44904d98-97be-4080-9a84-bf5742525f8e
Ball, D
130db4c5-0721-4d6d-88d3-e502f5610b55
Barrett, C
22ed24c2-7305-4293-97df-4a27d9dd4e0a
Johnson, L
9f854b21-5ab6-42b1-a11e-f9871128f8fa
Nuttall, J
154aec0a-05f2-4379-918e-9c36767fdc4c
Fox, K.
cb14d631-49e0-4eaa-9c31-bc8fa56bcf62
Connolly, D
6067c40f-49e1-4d57-be94-b8753eee8230
O'Kane, P
2b488230-e0b8-4bec-9eb6-b6e071d25cd8
Hobson, A
7d245a8e-2a69-417c-81ae-5d8c6b775897
Chauhan, A
8e0ac32a-b41d-44cf-9e17-2395913dfee5
Uren, N
d13a24cc-01a4-4a8c-a522-b1b5fd872e4a
Mccann, G P
8e61a5f4-0764-4adf-bc9c-5abba82425fc
Berry, C
9d729b5b-d244-42bc-a44e-ad74874d9d2d
Carter, J
e05be2f9-991d-4476-bb50-ae91606389da
Roobottom, C
990efe11-c995-4beb-b262-59ae97269bad
Mamas, M
41515b72-75ff-4922-bb9f-8f9c63f9f5af
Rajani, R
f2c3a772-ab0a-459e-b820-e4dcc0339d41
Ford, I
02bcd593-64e4-4cb9-87e3-9a6efe4d155c
Douglas, P
003c913d-4d22-44e3-a74c-83ee06241947
Hlatky, M.A.
43f00437-a3e4-4f81-aed9-5b0ca52cd86e